Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report.

IF 0.7 Q4 ONCOLOGY

Case Reports in Oncology Pub Date : 2024-10-03 eCollection Date: 2024-01-01 DOI:10.1159/000540842

Sara Cerqueira Cabral, Emanuel Gouveia, Hugo Nunes, Patricia M Pereira

{"title":"Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report.","authors":"Sara Cerqueira Cabral, Emanuel Gouveia, Hugo Nunes, Patricia M Pereira","doi":"10.1159/000540842","DOIUrl":null,"url":null,"abstract":"Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting.Case presentation: Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection.Conclusion: This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1109-1114"},"PeriodicalIF":0.7000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000540842","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting.

Case presentation: Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection.

Conclusion: This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.

查看原文本刊更多论文

在局部晚期不可切除皮肤鳞状细胞癌中使用术前免疫疗法：病例报告。

简介：皮肤鳞状细胞癌（cSCC）是第二大常见皮肤癌：皮肤鳞状细胞癌（cSCC）是第二大常见皮肤癌。手术是治愈局部疾病的标准治疗方法，但对于大面积头颈部 cSCC 而言，手术与高发病率相关。Cemiplimab是一种抗程序性细胞死亡-1（PD-1）蛋白的抗体，对局部晚期不可切除或转移性cSCC有效。一项试点研究表明，在新辅助治疗中使用塞米普利单抗可获得较高的病理完全应答率：在此，我们报告了一名84岁男性患者的病例，他患有两处局部晚期不可切除的cSCC（一处鼻唇沟病变和一处耳后病变），接受了cemiplimab治疗，经过4个周期的密切随访，耳后病变获得了完全应答，鼻唇沟病变获得了部分应答。患者将接受鼻唇病变切除术：结论：这说明了在晚期不可切除的 cSCC 中使用 cemiplimab 作为术前治疗的疗效，有助于最终的手术治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊